213 related articles for article (PubMed ID: 36686294)
21. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
22. Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors.
Hui KH; Pfeiffer ML; Esmaeli B
Saudi J Ophthalmol; 2012 Oct; 26(4):365-71. PubMed ID: 23961021
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
[TBL] [Abstract][Full Text] [Related]
24. [Positron emission tomography-computed tomography in tumors of the locomotor apparatus].
Gámez Cenzano C; Sabaté Llobera A; Narváez García JA; Rodríguez Bel L; García del Muro FJ
Radiologia; 2012 Sep; 54 Suppl 1():3-13. PubMed ID: 22959330
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in the Detection of Malignant Gastrointestinal Stromal Tumor.
Zhang Z; Jiang H; Zhang L; Cheng C; Zuo C
Clin Nucl Med; 2023 Jan; 48(1):61-63. PubMed ID: 36469061
[TBL] [Abstract][Full Text] [Related]
27. Advantages of percutaneous abdominal biopsy under PET-CT/ultrasound fusion imaging guidance: a pictorial essay.
Paparo F; Piccazzo R; Cevasco L; Piccardo A; Pinna F; Belli F; Bacigalupo L; Biscaldi E; De Caro G; Rollandi GA
Abdom Imaging; 2014 Oct; 39(5):1102-13. PubMed ID: 24777592
[TBL] [Abstract][Full Text] [Related]
28. The impact of multimodality integrated positron emission tomography-computed tomography on improving the staging and management of head and neck malignancy: a cross- sectional study.
Subha ST; Nordin AJ
Sao Paulo Med J; 2022; 140(3):454-462. PubMed ID: 35507996
[TBL] [Abstract][Full Text] [Related]
29. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer.
Duncan JR; Carr D; Kaffenberger BH
J Am Acad Dermatol; 2016 Jul; 75(1):186-96. PubMed ID: 26992283
[TBL] [Abstract][Full Text] [Related]
30. Nonspecific Uptake of
Malik D; Sood A; Mittal BR; Singh H; Basher RK; Shukla J; Bhattacharya A; Singh SK
Indian J Nucl Med; 2018; 33(4):317-325. PubMed ID: 30386054
[No Abstract] [Full Text] [Related]
31.
Cherk MH; Nadebaum DP; Barber TW; Beech P; Haydon A; Yap KS
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):483-494. PubMed ID: 35191204
[No Abstract] [Full Text] [Related]
32. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
33. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of fluorodeoxyglucose positron emission tomography/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography/computed tomography.
Nakajo K; Tatsumi M; Inoue A; Isohashi K; Higuchi I; Kato H; Imaizumi M; Enomoto T; Shimosegawa E; Kimura T; Hatazawa J
Jpn J Radiol; 2010 Feb; 28(2):95-100. PubMed ID: 20182843
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses.
D'Angelo EC; Paolisso P; Vitale G; Foà A; Bergamaschi L; Magnani I; Saturi G; Rinaldi A; Toniolo S; Renzulli M; Attinà D; Lovato L; Lima GM; Bonfiglioli R; Fanti S; Leone O; Saponara M; Pantaleo MA; Rucci P; Di Marco L; Pacini D; Pizzi C; Galiè N
JACC Cardiovasc Imaging; 2020 Nov; 13(11):2400-2411. PubMed ID: 32563654
[TBL] [Abstract][Full Text] [Related]
37. The Role of Positron Emission Tomography for the Management of Sinonasal Malignancies: A Systematic Review.
El-Adem D; Yang N; Gudis DA
Am J Rhinol Allergy; 2023 Sep; 37(5):593-610. PubMed ID: 37229633
[TBL] [Abstract][Full Text] [Related]
38. Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
Smyth EC; Shah MA
World J Gastroenterol; 2011 Dec; 17(46):5059-74. PubMed ID: 22171140
[TBL] [Abstract][Full Text] [Related]
39. Utility of different positron emission tomography/computed tomography tracers in the evaluation of incidentally detected dual malignancies: An experience from a tertiary care center.
Kumar RE; Gupta N; Verma R; Belho ES
World J Nucl Med; 2021; 20(4):382-385. PubMed ID: 35018156
[TBL] [Abstract][Full Text] [Related]
40. Discordant Primary Resistance to Imatinib Mesylate in the Same Individual and Splenic Involvement in Recurring Gastric Gastrointestinal Stromal Tumors: Assessment by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.
Fargose P; Basu S
Indian J Nucl Med; 2018; 33(2):140-142. PubMed ID: 29643676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
